Management of female stress urinary incontinence: A care pathway and update

Capobianco, Giampiero; Madonia, Massimo; Morelli, Sônia Maria Dornellas; Dessole, Francesco; Vita, Davide De; Cherchi, Pl; Dessole, Salvatore

doi:10.1016/j.maturitas.2017.12.008

Cited by 81 publications

(58 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The EA protocol was the same as that in the SUI trial. All patients in the other group received PFMT once per week for weeks [1][2][3][4][5][6][7][8][9][10][11][12] and once every four weeks for weeks 13-36, plus oral solifenacin 5 mg daily over the entire 36 weeks. Detailed study methods and results of the MUI trial have been published.…”

Section: The Ea Vs Pfmt Plus Solifenacin For Mui Trialmentioning

confidence: 99%

“…Stress urinary incontinence (SUI) symptoms include any involuntary loss of urine related to effort, physical exertion, sneezing or coughing, and are common in SUI and stress‐predominant mixed urinary incontinence (S‐MUI) conditions . The prevalence of urinary incontinence (UI) varies according to the population of interest and the definition applied.…”

Section: Introductionmentioning

confidence: 99%

“…For SUI in obese women, the international guidelines suggest weight loss as the initial treatment plan, and data support that a weight loss of 5%‐10% is similarly efficient to that of other non‐surgical UI treatments . Also, other conservative management plans for SUI or S‐MUI combine many methods that include behavioural modification, pelvic floor muscle training (PFMT), pharmacotherapy and anti‐incontinence devices . For whom traditional methods have failed, surgical intervention (eg, urethral bulking agents and sling procedures) is recommended.…”

Section: Introductionmentioning

confidence: 99%

“…12 Also, other conservative management plans for SUI or S-MUI combine many methods that include behavioural modification, pelvic floor muscle training (PFMT), pharmacotherapy and anti-incontinence devices. 1,15 For whom traditional methods have failed, surgical intervention (eg, urethral bulking agents and sling procedures 9 ) is recommended. However, what calls for special attention is that as obesity might be associated with the weakening of pelvic floor innervation and musculature 13 that results from increased IAP, treatment of such patients may be more difficult to satisfy with treatment effects.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Comparing the effect of electroacupuncture treatment on obese and non‐obese women with stress urinary incontinence or stress‐predominant mixed urinary incontinence: A secondary analysis of two randomised controlled trials

Wang

Liu

et al. 2019

Int J Clin Pract

View full text Add to dashboard Cite

Objective To explore whether obesity patients with a body mass index (BMI) of ≥25 kg/m2 who suffer from stress urinary incontinence (SUI) or stress‐predominant mixed urinary incontinence (S‐MUI) show less improvement in urinary incontinence (UI) symptoms after electroacupuncture (EA) treatment compared with non‐obese counterparts. Methods This study was a secondary analysis of existing data. About 252 SUI patients and 250 S‐MUI patients treated with the same EA regimen were assigned to one of the two groups: the obesity group for BMI ≥25 kg/m2 and the non‐obesity group for BMI <25 kg/ m2. The primary outcome was the proportion of treatment responders, defined as patients exhibiting a ≥50% reduction in 72‐hours incontinence episode frequency, as measured by a 72‐hours bladder diary at week 6 compared with baseline. Results Of the 1004 randomised women, 129 obese women (86 SUI and 43 S‐MUI) and 255 non‐obese women (166 SUI and 89 S‐MUI) treated with EA were included in a secondary analysis. The primary outcome was that 58.3% (74/127) of patients in the obesity group and 60.7% (150/247) of patients in the non‐obesity group (difference 0.55%; 95% confidence interval, −10.01 to 11.11; P = .919) responded to treatment. Conclusion This study suggests that EA treatment may safely improve UI symptoms in both obese and non‐obese patients, regardless of BMI category. Additionally, obesity status may not affect the efficacy of EA treatment on SUI or S‐MUI among Chinese women.

show abstract

Section: The Ea Vs Pfmt Plus Solifenacin For Mui Trialmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Comparing the effect of electroacupuncture treatment on obese and non‐obese women with stress urinary incontinence or stress‐predominant mixed urinary incontinence: A secondary analysis of two randomised controlled trials

Wang

Liu

et al. 2019

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…4 Female stress urinary incontinence (SUI) is the involuntary leakage of urine during events that result in increased abdominal pressure in the absence of a bladder contraction due to effort or exertion or on sneezing or coughing. 5 In 2017, estimates of its prevalence in the female population range from 10% to 40%. 6,7 SUI is associated with significant impairment in quality of life and has a significant socioeconomic impact, with costs steadily increasing as the population ages.…”

mentioning

confidence: 99%

Two phase I/II clinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells

García‐Arranz

Alonso-Gregorio

Fontana-Portella

et al. 2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

We proposed to evaluate the safety and feasibility of adipose-derived mesenchymal stem cells to treat endoscopically urinary incontinence after radical prostatectomy in men or female stress urinary. We designed two prospective, nonrandomized phase I-IIa clinical trials of urinary incontinence involving 9 men (8 treated) and 10 women to test the feasibility and safety of autologous mesenchymal stem cells for this use. Cells were obtained from liposuction containing 150 to 200 g of fat performed on every patient. After 4 to 6 weeks and under sedation, endoscopic intraurethral injection of the cells was performed. On each visit (baseline, 1, 3, 6, and 12 months), clinical parameters were measured, and blood samples, urine culture, and uroflowmetry were performed. Every patient underwent an urethrocystoscopy and urodynamic studies on the first and last visit. Data from pad test, quality-of-life and incontinence questionnaires, and pads used per day were collected at every visit. Statistical analysis is made by Wilcoxon signed-rank test. No adverse effects have been collected. Three men (37.5%) and five women (50%) showed an objective improvement of >50% (P < .05) and a subjective improvement of 70% to 80% from baseline. In conclusion, intraurethral application of stem cells derived from adipose tissue is a safe and feasible procedure to treat urinary incontinence after radical prostatectomy or in female stress urinary incontinence. A statistically significant difference was obtained for pad-test improvement in 3/8 men and 5/10 women. Our results encourage studies to confirm safety and to analyze efficacy. K E Y W O R D S adipose-derived stem cells, cellular therapy, male/female urinary incontinence, phase IIa clinical trial 1 | INTRODUCTION The International Continence Society defines urinary incontinence as "any involuntary loss of urine that is a social or hygienic problem." Following benign prostatic hyperplasia surgery, a mean of 0.5% to 2%

show abstract

A systematic review of stem cell therapy treatment for women suffering from stress urinary incontinence

Klapper-Goldstein

Tamam

Sade

et al. 2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Background Stem cell therapy (SCT) is used for regeneration of injured tissues. This seems a novel promising strategy for restoring urethral sphincter function in patients with stress urinary incontinence (SUI). Objective To summarize the clinical trials available to date on SCT for treatment of SUI in women. Search strategy PubMed, Cochrane Library, Scopus and Embase. Selection criteria Prospective interventional case series, randomized prospective interventional study and prospective cohort study assessing women aged 18 years and over diagnosed with SUI and treated by SCT were included. The quality of studies was finally assessed using the JBI Critical Appraisal Checklists according to the PRISMA guidelines. Data collection and analysis Nineteen studies (n = 773 patients) were selected for final analysis. These were conducted worldwide between the years 2005 and 2016. Although different cell types were used, general processing steps were similar. The follow‐up period ranged between 6 weeks and 6 years and included common subjective and objective evaluation tools. Results Overall, the studies imply that SCT for treatment of SUI is a safe and effective treatment. Conclusion In our opinion, the initial results of SCT for the treatment of SUI seem promising. Standardization and validation of this treatment modality is required before it can be recommended for routine use.

show abstract

Management of female stress urinary incontinence: A care pathway and update

Cited by 81 publications

References 45 publications

Comparing the effect of electroacupuncture treatment on obese and non‐obese women with stress urinary incontinence or stress‐predominant mixed urinary incontinence: A secondary analysis of two randomised controlled trials

Comparing the effect of electroacupuncture treatment on obese and non‐obese women with stress urinary incontinence or stress‐predominant mixed urinary incontinence: A secondary analysis of two randomised controlled trials

Two phase I/II clinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells

A systematic review of stem cell therapy treatment for women suffering from stress urinary incontinence

Contact Info

Product

Resources

About